Skip to main content
Clinical Trials/NCT02700633
NCT02700633
Unknown
Not Applicable

Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI

Royal Sussex County Hospital0 sites4,000 target enrollmentFebruary 2016
ConditionsTAVI

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
TAVI
Sponsor
Royal Sussex County Hospital
Enrollment
4000
Primary Endpoint
30 day mortality
Last Updated
10 years ago

Overview

Brief Summary

Pacemaker requirement in the immediate post procedure phase following TAVI is approximately 20% depending on device type and patient characteristics. There is a signal from recent studies suggesting increased risk of sudden cardiac / unexplained death in the first 30-60 days. This study aims to address whether there is a mortality advantage to having a pacemaker in the short term

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
July 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Royal Sussex County Hospital
Responsible Party
Principal Investigator
Principal Investigator

David Hildick-Smith

Consultant Cardiologist

Royal Sussex County Hospital

Eligibility Criteria

Inclusion Criteria

  • All patients post TAVI

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

30 day mortality

Time Frame: 30 dyas

Secondary Outcomes

  • 60 day mortality(60 days)

Similar Trials